By otakuyassine3@gmail.com 
AnaptysBio (NASDAQ:ANAB – Get Free Report) had its target price decreased by equities research analysts at JPMorgan Chase & Co. from $66.00 to $36.00 in a research report issued on Thursday,Benzinga reports. The brokerage currently has an “overweight” rating on the biotechnology company’s stock. JPMorgan Chase & Co.‘s price target indicates a potential upside of 139.52% from the company’s current price.
A number of other research firms have also issued reports on ANAB. Wedbush restated an “outperform” rating and set a $40.00 price objective (down previously from $42.00) on shares of AnaptysBio in a research report on Wednesday, December 11th. HC Wainwright downgraded AnaptysBio from a “buy” rating to a “neutral” rating and reduced their price objective for the stock from $52.00 to $19.00 in a research report on Wednesday, December 11th. UBS Group increased their target price on shares of AnaptysBio from $23.00 to $33.00 and gave the company a “neutral” rating in a research report on Wednesday, October 30th. BTIG Research cut AnaptysBio from a “buy” rating to a “neutral” rating in a research report on Monday, December 2nd. Finally, Guggenheim lowered their price objective on shares of AnaptysBio from $90.00 to $36.00 and set a “buy” rating on the stock in a research note on Thursday, December 12th. Four analysts have rated the stock with a hold rating and eight have assigned a buy rating to the stock. According to data from MarketBeat, AnaptysBio has a consensus rating of “Moderate Buy” and an average price target of $41.45.
Check Out Our Latest Stock Report on ANAB
AnaptysBio Price Performance
ANAB stock traded down $0.31 during midday trading on Thursday, reaching $15.03. 114,525 shares of the company’s stock traded hands, compared to its average volume of 383,324. The business has a 50-day moving average price of $24.59 and a two-hundred day moving average price of $29.31. AnaptysBio has a fifty-two week low of $14.20 and a fifty-two week high of $41.31. The company has a market capitalization of $457.35 million, a P/E ratio of -2.47 and a beta of -0.11.
AnaptysBio (NASDAQ:ANAB – Get Free Report) last posted its quarterly earnings data on Tuesday, November 5th. The biotechnology company reported ($1.14) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($1.72) by $0.58. The company had revenue of $30.02 million for the quarter, compared to analyst estimates of $7.92 million. AnaptysBio had a negative net margin of 289.75% and a negative return on equity of 287.94%. As a group, research analysts forecast that AnaptysBio will post -6.02 earnings per share for the current fiscal year.
Insider Buying and Selling
In related news, insider Paul F. Lizzul sold 1,500 shares of AnaptysBio stock in a transaction dated Monday, September 23rd. The stock was sold at an average price of $38.67, for a total transaction of $58,005.00. Following the sale, the insider now directly owns 15,398 shares of the company’s stock, valued at $595,440.66. This trade represents a 8.88 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Insiders own 33.70% of the company’s stock.
Institutional Trading of AnaptysBio
Institutional investors have recently made changes to their positions in the business. Values First Advisors Inc. acquired a new position in AnaptysBio during the 3rd quarter worth about $49,000. nVerses Capital LLC lifted its holdings in AnaptysBio by 700.0% in the third quarter. nVerses Capital LLC now owns 1,600 shares of the biotechnology company’s stock valued at $54,000 after buying an additional 1,400 shares during the period. Headlands Technologies LLC raised its position in shares of AnaptysBio by 444.8% during the 2nd quarter. Headlands Technologies LLC now owns 3,552 shares of the biotechnology company’s stock valued at $89,000 after acquiring an additional 2,900 shares during the last quarter. China Universal Asset Management Co. Ltd. grew its stake in shares of AnaptysBio by 81.0% during the third quarter. China Universal Asset Management Co. Ltd. now owns 5,808 shares of the biotechnology company’s stock worth $195,000 after purchasing an additional 2,600 shares during the period. Finally, Point72 DIFC Ltd boosted its stake in AnaptysBio by 680.5% during the 3rd quarter. Point72 DIFC Ltd now owns 6,127 shares of the biotechnology company’s stock worth $205,000 after acquiring an additional 5,342 shares during the last quarter.
About AnaptysBio
AnaptysBio, Inc, a clinical-stage biotechnology company, focuses in delivering immunology therapeutics. Its products include Rosnilimab, an IgG1 antibody that targets PD-1+ T cells, resulting in their agonism or depletion, broadly impacting pathogenic drivers of autoimmune and inflammatory diseases; and ANB032, a non-depleting antibody that binds to the BTLA checkpoint receptor and inhibits activated T cell proliferation; ANB033, a novel anti-CD122 antagonist antibody that targets the shared common beta subunit of the receptors for IL-15 and IL-2; ANB101, a BDCA2 modulator antibody that specifically targets plasmacytoid dendritic cells (pDCs); and Imsidolimab, an antibody that inhibits the interleukin-36 receptor, which is in the Phase 3 development for the treatment of generalized pustular psoriasis.
Read More
Receive News & Ratings for AnaptysBio Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for AnaptysBio and related companies with MarketBeat.com’s FREE daily email newsletter.